中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 7
Jul.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(7): 1632-1637

Efficacy of atezolizumab combined with bevacizumab versus sintilimab combined with bevacizumab biosimilar in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH260720

  • Department of Oncology，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Special Project for Cancer Research of the Department of Oncology, Capital Medical University for the Year 2026 (ZLXXKYZX-2026-06)

More Information
  • Corresponding author: Li Wendong， 13718973845@163.com （ORCID： 0000-0002-9296-651X）
  • Received Date: 2026-03-14
  • Accepted Date: 2026-04-30
  • Published Date: 2026-07-25
    Abstract
  •   Objective  To investigate the efficacy and safety of atezolizumab combined with bevacizumab versus sintilimab combined with bevacizumab biosimilar in the treatment of patients with unresectable hepatocellular carcinoma （HCC） in a real-world setting， and to provide a reference for clinical practice.  Methods  A retrospective analysis was performed for 130 patients with unresectable HCC who were treated in Beijing Ditan Hospital， Capital Medical University， from January 2020 to January 2026， and all patients received the first-line systemic therapy with immune checkpoint inhibitors combined with bevacizumab or its biosimilar. According to the treatment regimen， the patients were divided into atezolizumab+bevacizumab group （T+A group with 51 patients） and sintilimab+bevacizumab biosimilar group （Shuangda group with 79 patients）. The primary endpoint was progression-free survival （PFS）， and secondary endpoints included objective response rate （ORR）， disease control rate （DCR）， and safety profile. The independent-samples t test or the Wilcoxon rank-sum test was used for comparison of continuous data between the two groups， and the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for survival analysis， and the Log-rank test was used for comparison between groups.  Results  The T+A group had a median PFS of 297.00 days （95% confidence interval ［CI］： 195.44 — 398.56）， and the Shuangda group had a median PFS of 236.00 days （95%CI： 165.10 — 306.90）， with no significant difference between the two groups （P=0.668）. There were no significant differences between the T+A group and the Shuangda group in ORR （56.9% vs 45.6%， χ2=1.581， P=0.209）， DCR （76.5% vs 77.2%， χ2=0.010， P=0.922）， and the incidence of adverse events （96.08% vs 94.94%， P>0.05）.  Conclusion  For unresectable HCC patients without prior systemic treatment， atezolizumab combined with bevacizumab can achieve a comparable PFS to sintilimab combined with bevacizumab biosimilar.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    Yang Yuze, Xu Jiahao, Yang Yishi, et al. Progress in neoadjuvant therapy for hepatocellular carcinoma[J/OL]. Chin J Liver Dis(Electronic Version), 2025, 14( 4): 515- 521. DOI: 10.3877/cma.j.issn.2095-3232.2025.04.003.

    杨钰泽, 徐家豪, 杨一石, 等. 肝细胞癌新辅助治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14( 4): 515- 521. DOI: 10.3877/cma.j.issn.2095-3232.2025.04.003.
    [3]
    He Ling, Liu Xiping. Current status and reflection of combination therapy in immunotherapy of hepatocellular carcinoma[J]. Chin J Immunol, 2026, 42( 3): 742- 748. DOI: 10.3969/j.issn.1000-484X.2026.03.036.

    何玲, 刘喜平. 联合疗法在肝细胞癌免疫治疗中的现状与思考[J]. 中国免疫学杂志, 2026, 42( 3): 742- 748. DOI: 10.3969/j.issn.1000-484X.2026.03.036.
    [4]
    Cheng A L, Qin S K, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
    [5]
    Ren Z G, Xu J M, Bai Y X, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
    [6]
    Lau G, Obi S, Zhou J, et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024[J]. Hepatol Int, 2024, 18( 6): 1661- 1683. DOI: 10.1007/s12072-024-10732-z.
    [7]
    Gordan J D, Kennedy E B, Abou-Alfa G K, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update[J]. J Clin Oncol, 2024, 42( 15): 1830- 1850. DOI: 10.1200/JCO.23.02745.
    [8]
    Suddle A, Reeves H, Hubner R, et al. British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults[J]. Gut, 2024, 73( 8): 1235- 1268. DOI: 10.1136/gutjnl-2023-331695.
    [9]
    Vogel A, Chan S L, Dawson L A, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2025, 36( 5): 491- 506. DOI: 10.1016/j.annonc.2025.02.006.
    [10]
    Marrero J A, Kulik L M, Sirlin C B, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68( 2): 723- 750. DOI: 10.1002/hep.29913.
    [11]
    Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45( 2): 228- 247. DOI: 10.1016/j.ejca.2008.10.026.
    [12]
    Lencioni R, Llovet J M. Modified RECIST(mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30( 1): 52- 60. DOI: 10.1055/s-0030-1247132.
    [13]
    U. S Department of Health& Human Service.CTCAE5.0[DB/OL]. https://www.hhs.gov/2017-11-27. https://www.hhs.gov/2017-11-27
    [14]
    Kudo M, Finn R S, Qin S K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391( 10126): 1163- 1173. DOI: 10.1016/S0140-6736(18)30207-1.
    [15]
    Finn R S, Qin S K, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [16]
    Yau T, Kang Y K, Kim T Y, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6( 11): e204564. DOI: 10.1001/jamaoncol.2020.4564.
    [17]
    Abou-Alfa G K, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma[J]. NEJM Evid, 2022, 1( 8): EVIDoa2100070. DOI: 10.1056/EVIDoa2100070.
    [18]
    Kikugawa C, Uchikawa S, Kawaoka T, et al. Outcomes of patients with child-pugh B and unresectable hepatocellular carcinoma undergoing first-line systemic treatment with sorafenib, lenvatinib, or atezolizumab plus bevacizumab[J]. Oncology, 2024, 102( 3): 239- 251. DOI: 10.1159/000533859.
    [19]
    Sasaki R, Shimose S, Saeki I, et al. Efficacy and safety of atezolizumab plus bevacizumab for patients with hepatocellular carcinoma and child-pugh class B[J]. Liver Int, 2026, 46( 1): e70466. DOI: 10.1111/liv.70466.
    [20]
    Zhang Y X, Miao Y H, Sun W, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) in advanced HCC with Child-Pugh A/B liver function: A real-world multicenter retrospective study[J]. Front Oncol, 2025, 15: 1681663. DOI: 10.3389/fonc.2025.1681663.
    [21]
    Li J, Bai Y W, Xiong F, et al. Atezolizumab plus bevacizumab combined with or without transarterial chemoembolization in the treatment of advanced hepatocellular carcinoma: A single-center retrospective study[J]. J Hepatocell Carcinoma, 2025, 12: 973- 984. DOI: 10.2147/JHC.S515453.
    [22]
    Zhang N N, Liu K P, Yu Y X, et al. Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: A multicenter cohort study[J]. Hepatol Int, 2025, 19( 6): 1382- 1396. DOI: 10.1007/s12072-025-10895-3.
    [23]
    Yang J J, Xu Q P, Wu S. Efficacy and safety of sintilimab plus a bevacizumab biosimilar combined with transarterial chemoembolization for advanced hepatocellular carcinoma[J]. Medicine, 2025, 104( 51): e46799. DOI: 10.1097/MD.0000000000046799.
    [24]
    Wang K, Feng J K, Yu H M, et al. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: A single-arm, phase 2 trial[J]. Sig Transduct Target Ther, 2025, 10: 328. DOI: 10.1038/s41392-025-02427-0.
    [25]
    Huang Z K, Chen T J, Li W B, et al. PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma[J]. Clin Exp Med, 2024, 24( 1): 138. DOI: 10.1007/s10238-024-01415-y.
    [26]
    Kim T, Shijo H, Kokawa H, et al. Risk factors for hemorrhage from gastric fundal varices[J]. Hepatology, 1997, 25( 2): 307- 312. DOI: 10.1053/jhep.1997.v25.pm0009021939.
    [27]
    Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: A meta-analysis[J]. Oncology, 2010, 79( 1-2): 27- 38. DOI: 10.1159/000314980.
    [28]
    Tada F, Hiraoka A, Tada T, et al. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices[J]. J Gastroenterol, 2023, 58( 11): 1134- 1143. DOI: 10.1007/s00535-023-02026-2.
    [29]
    Kamel M M, Saad M F, Mahmoud A A, et al. Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma[J]. Microb Pathogen, 2014, 77: 31- 35. DOI: 10.1016/j.micpath.2014.10.009.
    [30]
    Xu F, Zhang L L, He W T, et al. The diagnostic value of serum PIVKA-II alone or in combination with AFP in Chinese hepatocellular carcinoma patients[J]. Dis Markers, 2021, 2021( 1): 8868370. DOI: 10.1155/2021/8868370.
    [31]
    Xu C H, Luo X Y, Fang X X, et al. AFP/PIVKA-II double-positive status indicates a high-risk subtype of hepatocellular carcinoma in liver transplantation: Retrospective cohort study and phosphoproteome evaluation[J]. Int J Surg, 2026, 112( 3): 7373- 7389. DOI: 10.1097/JS9.0000000000004101.
    [32]
    Jiang S S, Wang Y Y, Fu X N, et al. Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors[J]. Ther Adv Med Oncol, 2025, 17: 17588359251386801. DOI: 10.1177/17588359251386801.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (73) PDF downloads(19) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return